Biocomposites exceeds revenue expectations and takes a big step forward in its research and development

New record for sales growth and number of patients supportedProduct portfolio enhanced through acquisition of NanoBone® and expansion of STIMULAN® approval as an antibiotic carrier to treat bacterial infectionResearch and Development boosts with STIMULAN VG moving to phase II clinical trial and investment in RenoviteView original content:https://www.prnewswire.co.uk/news-releases/biocomposites-exceeds-revenue-expectations-and-takes-a-big-step-forward-in-its-research-and-development-302012661.html

en | CA7609751028 | BIOCOMPOSITES | boerse | 67933059 |